<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065347</url>
  </required_header>
  <id_info>
    <org_study_id>19-0715</org_study_id>
    <secondary_id>1R01AI145453-01A1</secondary_id>
    <nct_id>NCT04065347</nct_id>
  </id_info>
  <brief_title>Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF)</brief_title>
  <official_title>Quantification of Tenofovir Alafenamide Adherence and Exposure in Adults Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the relationship between adherence to antiretroviral
      therapy (ART) and HIV drug concentrations in persons living with HIV (PLWH) that are taking
      tenofovir alafenamide (TAF). Adherence will be measured with an ingestible biosensor (digital
      pill). Antiretroviral drug concentrations will be measured in different types of blood cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PLWH taking or initiating/re-initiating TAF will be recruited for a 16-week study. Upon
      entering the study, participants will be trained on the use the digital pill to objectively
      quantify adherence. Study participants already taking TAF will return every 4 weeks for a
      study visit where blood for drug concentrations will be obtained. Participants
      initiating/re-initiating TAF will return weekly for the first 4 weeks, at weeks 6 and 8, and
      every 4 weeks thereafter for a study visit where drug concentrations will be obtained.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 21, 2019</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)</measure>
    <time_frame>Week 12</time_frame>
    <description>Steady-state drug concentration distribution and quantiles for highly adherent (i.e. &gt;95% of ingestions) participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)</measure>
    <time_frame>Week 16</time_frame>
    <description>Steady-state drug concentration distribution and quantiles for highly adherent (i.e. &gt;95% of ingestions) participants.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">212</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Adherence, Medication</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>A total of 150 participants taking tenofovir alafenamide will be enrolled in this cohort.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>A total of 30 participants initiating/re-initiating tenofovir alafenamide will be enrolled in this cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Digital Pill</intervention_name>
    <description>Digital Pill over encapsulating tenofovir alafenamide ART</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>etectRx ID-Cap System</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        PLWH who are initiating/re-initiating or have been on TAF for &gt; 6 months.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females or males with HIV, able to give informed consent and comply with study
             procedures.

          2. Currently on (&gt; 6 months), or planning to initiate/re-initiate TAF.

        Exclusion Criteria:

          1. For females of childbearing age, active pregnancy or any intent to become pregnant

          2. Hepatitis C (HCV) infection for which treatment is anticipated within the next 16
             weeks after enrollment. Treated HCV with sustained virologic response is allowable if
             last dose of HCV antivirals was &gt;12 months prior to enrollment

          3. Advanced renal (eGFR &lt;30 mL/min/1.73m**2) or liver (Child-Pugh B or C) disease

          4. History of extensive bowel surgery, gastric bypass, or gastroparesis

          5. Concomitant use of any prescription or non-prescription drug known (or with the
             potential) to significantly influence the PK of TAF (e.g. rifamycins, carbamazepine,
             phenytoin, St. John's Wort, tipranavir)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose R Castillo-Mancilla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado-AMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryan P Coyle, BA</last_name>
    <phone>303-724-8612</phone>
    <email>ryan.coyle@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jose R Castillo-Mancilla, MD</last_name>
    <phone>303-724-4934</phone>
    <email>jose.castillo-mancilla@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adherence</keyword>
  <keyword>Dried Blood Spots</keyword>
  <keyword>Tenofovir-diphosphate</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <keyword>Tenofovir alafenamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

